一致B(200028) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥16,049,966,325.75, representing a 25.15% increase compared to ¥12,824,196,278.66 in the same period last year[8]. - Net profit attributable to shareholders was ¥328,800,560.24, up 32.15% from ¥248,800,655.88 year-on-year[8]. - Basic earnings per share increased to ¥0.77, a rise of 32.76% compared to ¥0.58 in the same period last year[8]. - Net profit increased by ¥944.76 million, a growth rate of 32.02%, driven by strong operational growth and increased revenue[21]. - Total comprehensive income increased by ¥945.6 million, a growth rate of 32.04%, attributed to operational growth and increased investment income[24]. - The total profit for the current period was ¥477,143,753.02, a rise of 28.0% from ¥372,880,163.60 in the prior period[69]. - The operating profit for the current period was ¥471,343,655.22, which is a 26.4% increase from ¥372,778,763.68 in the previous period[69]. Cash Flow - The net cash flow from operating activities improved significantly, with a net cash outflow of ¥306,748,999.24, a 55.43% reduction from the previous year's outflow of ¥688,273,848.63[8]. - Operating cash flow increased by ¥381.52 million, a growth rate of 55.43%, due to higher sales revenue[24]. - The company recorded a cash inflow from operating activities of ¥15,194,724,502.12, compared to ¥13,201,992,638.81 in the previous period, indicating a growth of 15.1%[77]. - Operating cash outflow amounted to CNY 15,716,836,979.93, compared to CNY 14,324,456,811.53 in the previous period[81]. - Net cash flow from operating activities was -CNY 306,748,999.24, an improvement from -CNY 688,273,848.63[81]. - Cash inflow from financing activities totaled CNY 870,692,451.42, an increase from CNY 623,256,184.75[83]. - Net cash flow from financing activities was CNY 388,524,014.89, a turnaround from -CNY 57,116,425.11[83]. Assets and Liabilities - Total assets at the end of the reporting period were ¥43,020,753,415.92, reflecting an 8.65% increase from ¥39,594,533,471.65 at the end of the previous year[8]. - The company's current assets totaled CNY 32,237,295,928.93, up from CNY 29,262,092,079.46 at the end of 2020, indicating an increase of about 6.7%[42]. - The total liabilities reached CNY 25,695,350,801.68, up from CNY 22,705,906,152.13, which is an increase of about 13.8%[48]. - The company's equity attributable to shareholders increased to CNY 14,277,162,387.04 from CNY 13,948,322,652.33, showing a growth of approximately 2.4%[51]. - The company's total non-current assets amounted to CNY 10,783,457,486.99, an increase from CNY 10,332,441,392.19, indicating a growth of approximately 4.4%[45]. Shareholder Information - The total number of shareholders at the end of the reporting period was 42,431, with the largest shareholder, China National Pharmaceutical Group, holding 56.06% of the shares[12]. - The company did not engage in any repurchase transactions among its top 10 shareholders during the reporting period[18]. Government Subsidies and Non-Recurring Items - The company received government subsidies amounting to ¥9,265,003.74 during the reporting period, which included various special subsidies and tax refunds[8]. - There were no non-recurring gains or losses classified as regular gains or losses during the reporting period[11]. Financial Ratios - The weighted average return on equity rose to 2.33%, an increase of 0.41 percentage points from 1.92% in the previous year[8]. - Financial expenses increased by ¥21.66 million, a growth rate of 74.67%, mainly due to higher interest expenses from supply chain financing[21].